| Biologic Therapy |
0 |
0.8 |
| Cancer |
0 |
0.81 |
| Skin Cancer |
0 |
0.81 |
| Prostate Cancer |
0 |
0.79 |
| COVID-19 |
0 |
0.99 |
| Noncolorectal Gastrointestinal Cancer |
0 |
0.7 |
| Lung Cancer |
0 |
0.68 |
| Colorectal Cancer |
0 |
0.64 |
| Gastric Cancer |
0 |
0.63 |
| Antineoplastic Drug |
0 |
0.61 |
| Cervical Cancer |
0 |
0.61 |
| Genomic Medicine |
0 |
0.56 |
| Small Cell Lung Cancer |
0 |
0.54 |
| Non-Small Cell Lung Cancer |
0 |
0.49 |
| Immunotherapy |
0 |
0.98 |
| Chemotherapy |
0 |
0.26 |
| Adjuvant Chemotherapy |
0 |
0.21 |
| Pandemic |
0 |
0.97 |
| Clinical Research |
0 |
1 |
| Immunization |
0 |
0.17 |
| Melanoma |
0 |
0.17 |
| Acute Respiratory Distress Syndrome |
0 |
0.09 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.09 |
| Europe |
0 |
0.09 |
| HIV Infection |
0 |
0.09 |
| Lung |
0 |
0.09 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.09 |
| Quality of Life |
0 |
0.09 |
| Severe Acute Respiratory Syndrome |
0 |
0.09 |
| Tyrosine Kinase Inhibitor |
0 |
0.09 |
| Esophageal Adenocarcinoma |
0 |
0.08 |
| Adenocarcinoma |
0 |
0.04 |
| Esophagus |
0 |
0.04 |
| Monoclonal Antibody |
0 |
0.04 |
| Neuroendocrine Tumor |
0 |
0.04 |
| Pheochromocytoma |
0 |
0.04 |
| Precision Medicine |
0 |
0.04 |
| Resection |
0 |
0.04 |
| Tumor |
0 |
0.04 |